Association of adjuvant tamoxifen and aromatase inhibitor therapy with contralateral breast cancer risk among us women with breast cancer in a general community setting

JAMA Oncology

Volumn 3, Issue 2, 2017, Pages 186-193

  Gierach, Gretchen L ^a   Curtis, Rochelle E ^a   Pfeiffer, Ruth M ^a   Mullooly, Maeve ^a   Ntowe, Estelle A ^a   Hoover, Robert N ^a   Nyante, Sarah J ^b   Feigelson, Heather Spencer ^c   Glass, Andrew G ^d   De Gonzalez, Amy Berrington ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; COHORT ANALYSIS; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 85018211908     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.3340     Document Type: Article

References (33)

1. Rosenberg PS, Barker KA, Anderson WF. Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States. J Natl Cancer Inst. 2015;107(9):djv159.
2. Curtis RE, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006. NIH publication 05-5302.
3. Davies C, Godwin J, Gray R, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-levelmeta-analysis of randomised trials. Lancet. 2011;378(9793):771-784.
4. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2(8449):282.
5. Davies KR, Cantor SB, Brewster AM. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int JWomens Health. 2015;7:181-187.
6. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209-219.
7. Bertelsen L, Bernstein L, Olsen JH, et al; Women's Environment, Cancer and Radiation Epidemiology Study Collaborative Group. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in theWomen's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008;100(1):32-40.
8. Cook LS,Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995;87(18):1359-1364.
9. Li CI, Daling JR, Porter PL, TangMT, Malone KE. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer [published corrections appear in Cancer Res. 2010;70(5):2140 and 2010;70(2):853]. Cancer Res. 2009;69(17):6865-6870.
10. Newcomb PA, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat. 1999;53(3):271-277.
11. Schaapveld M, Visser O, LouwmanWJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110(1):189-197.
12. Bouchardy C, Benhamou S, Fioretta G, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat. 2011;127(1):233-241.
13. Mellemkjær L, Steding-Jessen M, Frederiksen K, et al. Risk of contralateral breast cancer after tamoxifen use among Danishwomen. Ann Epidemiol. 2014;24(11):843-848.
14. Aihara T, Tanaka S, Sagara Y, et al. Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy. Breast Cancer. 2014;21(3):284-291.
15. Kuo WH, Yen AM, Lee PH, et al. Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast Cancer Res Treat. 2006;99(2):221-228.
16. Mason BH, Holdaway IM, Benton NM, Benson-Cooper DM, Hadden WE, Kay RG. Detection of contralateral breast cancer by mammography in women with previous breast cancer and the impact of endocrine therapy.N Z Med J. 1993;106(949):23-25.
17. Xing B, Huang X,Wang Y. The effect of long-term tamoxifen therapy on the occurrence of contralateral primary breast cancer [in Chinese]. Zhonghua Zhong Liu Za Zhi. 1996;18(2):143-145.
18. Gooley TA, LeisenringW, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
19. Epicure [Computer program]. Version 2.10. Seattle,WA: HiroSoft International Corp; 1998.
20. Nordenskjöld B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst. 2005;97(21): 1609-1610.
21. Hackshaw A, Roughton M, Forsyth S, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol. 2011;29(13):1657-1663.
22. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255-2269.
23. Arpino G,Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005;23 (21):4687-4694.
24. Burstein HJ, Prestrud AA, Seidenfeld J, et al; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784-3796.
25. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518.
26. Cuzick J, Sestak I, Baum M, et al; ATAC/LATTE Investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.
27. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst. 1991;83(18):1278-1280.
28. Johnston SR. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits. Lancet. 2016;387(10021):819-821.
29. Cuzick J, Sestak I, Bonanni B, et al; SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827-1834.
30. Wong SM, Freedman RA, Sagara Y, Aydogan F, BarryWT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer [published online March 8, 2016]. Ann Surg.
31. Sawesi S, Carpenter JS, Jones J. Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review. Clin J Oncol Nurs. 2014;18(3): E50-E57. doi:10.1188/14.CJON.E50-E57
32. Partridge AH,Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602-606.
33. Hershman DL, Tsui J, Meyer J, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst. 2014;106(11):dju319.